Anixa Biosciences presents breast cancer vaccine Phase 1 data showing all major endpoints met
ANIX•Anixa Biosciences said its Phase 1 breast cancer vaccine trial met all major endpoints. Of 35 patients dosed, 74% showed the protocol-specified immune response, and no safety concerns were reported.
1. Trial results and next steps
Anixa Biosciences completed its Phase 1 breast cancer vaccine trial, with Phase 2 enrollment as the next milestone. Combining the vaccine with Keytruda produced no additional adverse effects. The company said its ovarian cancer candidate, lira-cel, remains in Phase 1 development, with periodic data releases tied to enrollment.
2. Cash position
Anixa reported $14 million in cash and short-term investments as of July 31, 2026, with no debt. Its cash burn was $7 million in the last fiscal year.
